GET DAILY SIGNALSAUTL: Assessing the +506% Upside to the $8.00 Analyst Target
Key Takeaways
- The central target of $8.00 is the arithmetic mean of seven verified analyst price targets, rounded to a clean level; the underlying mean is approximately $8.11.
- At a recent price near $1.32, reaching $8.00 would require upside of roughly 506%, a very large move.
- The verified target range is wide, spanning roughly $5.00 to $10.00, reflecting genuine disagreement about the commercial and pipeline value of the company.
- Strongest supports are rapid AUTL revenue growth from its AUCATZYL CAR-T therapy, sharply improving gross margins, and an expanding autoimmune-disease pipeline.
- Biggest risks are persistent net losses, a flattening quarter-over-quarter launch curve, and delayed readouts in key pipeline indications.
- Readers can find more detail on the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots for additional AI-driven tools that monitor price action and changing market trends.
Breaking Down the Analyst Targets for AUTL
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company (a U.S.-listed American Depositary Receipt) developing CAR-T (chimeric antigen receptor T-cell) therapies for cancer and autoimmune diseases. Across reputable aggregators, sell-side coverage is predominantly positive, with the stock carrying a "Strong Buy" or "Moderate Buy" consensus and no Hold or Sell ratings among tracked firms.
For this analysis, seven individually attributable, current targets were reviewed: Needham (Gil Blum) at $10, H.C. Wainwright (Emily Bodnar) at $10, Mizuho Securities (Salim Syed) at $10, Leerink Partners at $8, Truist Financial at $8, Goldman Sachs at $5.80, and Wells Fargo at $5. These produce a low-to-high range of about $5 to $10 and a calculated mean near $8.11, rounded to the $8.00 central target used here. Some aggregators show a slightly higher or lower average and a high end near $11, underscoring how sensitive the figure is to which reports are included. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion is meaningful. The $10 targets generally emphasize the underappreciated value of the obe-cel platform in autoimmune disease, while the $5 to $5.80 targets place more weight on near-term commercial execution and profitability. This spread is not unusual for a pre-profit biotech whose value depends heavily on pipeline data that has not yet read out.
Current Market Position and Path Toward the Target
The shares recently traded near $1.32, toward the lower end of a 52-week range of roughly $1.12 to $2.58. Reaching the $8.00 central target would require a gain of about 506%, a very large move that implies a multi-year re-rating rather than an incremental step.
The company's lead product, AUCATZYL (obecabtagene autoleucel, or obe-cel), is an FDA-approved CD19 CAR-T therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Third-quarter 2026 net product revenue rose roughly 95% year over year to $41.2 million, and full-year 2026 guidance was raised to at or above the upper end of $150 million. Gross margin improved to about 57%, and the U.S. treatment-center network expanded to roughly 90 sites. Even so, the company remains unprofitable on a GAAP (generally accepted accounting principles) basis, and revenue dipped sequentially from the prior quarter, which helps explain why the market price and analyst targets remain far apart.
What Could Support a Move Toward the Target
- Commercial ramp: AUCATZYL revenue has grown strongly, and management has raised guidance multiple times in 2026.
- Margin expansion: Gross margin turned sharply positive and is trending toward a targeted 65–70% over time.
- Pipeline optionality: obe-cel is being studied in lupus and lupus nephritis (where the FDA granted RMAT, or Regenerative Medicine Advanced Therapy, designation) and progressive multiple sclerosis, with additional data expected through 2027.
- Balance-sheet runway: Reported cash of roughly $248 million is expected to fund operations into the second quarter of 2028.
What Could Prevent the Target From Being Reached
- Profitability gap: The company still posts significant net losses and is far from breakeven.
- Launch trajectory: The sequential sales dip suggests the growth curve may be flattening as the initial launch phase matures.
- Pipeline timing: A key readout in progressive multiple sclerosis was pushed to late 2027, delaying a potential value driver.
- Competition and safety: The CD19 CAR-T field is crowded, and safety questions around CAR-T in autoimmune disease remain an overhang.
- Financial flexibility: Shareholders' equity has contracted sharply, leaving less cushion if growth stalls or additional financing is needed.
Technical Levels and Market Structure
The stock is trading near multi-month lows and below both its 50-day (around $1.87) and 200-day (around $1.67) moving averages, indicating a prevailing downtrend. The 52-week low near $1.12–$1.20 represents a key support zone, while prior congestion near $1.50–$1.80 and the 52-week high around $2.58 mark notable resistance. A durable recovery toward the $8 target would likely require the shares to first reclaim and hold levels above those moving averages, a structurally significant task given current positioning.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ, and some targets implicitly embed longer-dated pipeline value. Investors should watch quarterly AUCATZYL sales and guidance updates, gross-margin trends, and cash position, as well as clinical data from lupus, lupus nephritis, and amyloidosis programs. Revisions to analyst targets, the delayed multiple sclerosis readout now expected in late 2027, and any changes to the financing picture are the most consequential variables for the gap between the current price and the target.
Using AI Daily Buy/Sell Signals in Practice
In my own analysis, I rely on Tickeron's AI Daily Buy/Sell Signals to apply artificial intelligence that continuously scans thousands of stocks and ETFs. This generates Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis, helping me surface opportunities and track shifts more efficiently than manual review alone.
Final Assessment
The question of whether Autolus Therapeutics can reach $8.00 hinges on the gap between a heavily discounted current valuation and a set of analyst targets that average far above today's price. The calculated mean of seven verified targets is roughly $8.11, but the wide $5-to-$10 range shows that even bullish analysts disagree sharply about how much the autoimmune pipeline and commercial trajectory are worth. Reaching the target would require a roughly 506% advance, a very large move that would likely depend on sustained AUCATZYL growth, continued margin gains, and positive clinical readouts. Persistent losses, a flattening launch curve, and pipeline delays represent the principal obstacles. Investors should monitor earnings, guidance, and clinical catalysts rather than treat the average target as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AUTL in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 39 cases where AUTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AUTL's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 31 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for AUTL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.498). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cancer treatments
Industry Biotechnology
Advertisement